European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia.
A. Hyperlipidaemia risk profiles should be identified by regular screening (at least once a year) for cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride blood levels in renal transplant patients. B. In renal transplant patients, hyperlipidaemia must be treated in order to keep the cholesterol/lipid levels within recommended limits according to the number of risk factors. C. Management of hyperlipidaemia after renal transplantation should be the same as for the dialysis population, with, in addition, modification of the immunosuppressive protocol when appropriate. D. Patients should be carefully monitored for adverse effects of lipid-lowering agents or interactions with immunosuppressive drugs.
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D016030:Kidney Transplantation / Q000009:adverse effects*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL